Dr. Tumeh’s overarching goal is to bridge the divide between medicine and science in the field of cancer immunotherapy. In the clinic, he serves melanoma patients who are being treated with various immunotherapies. In his translational immunology lab, Dr. Tumeh is focused on defining the phenotype and function of PD-L1+ myeloid-derived cells and understanding how these cells impact treatment outcomes with PD-1/PD-L1 blocking therapies.

Dr. Tumeh’s lab has established approaches including quantitative multiplexed immunohistochemistry, immune laser-capture microdissection, and spatially resolved gene expression profiling. His most recent publications include articles in Nature, New England Journal of Medicine, and Clinical Cancer Research.